These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10871311)

  • 1. Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.
    Trabace L; Cassano T; Steardo L; Pietra C; Villetti G; Kendrick KM; Cuomo V
    J Pharmacol Exp Ther; 2000 Jul; 294(1):187-94. PubMed ID: 10871311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor.
    Trabace L; Cassano T; Loverre A; Steardo L; Cuomo V
    CNS Drug Rev; 2002; 8(1):53-69. PubMed ID: 12070526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels.
    Trabace L; Cassano T; Cagiano R; Tattoli M; Pietra C; Steardo L; Kendrick KM; Cuomo V
    Brain Res; 2001 Aug; 910(1-2):182-6. PubMed ID: 11489269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurochemical and neurobehavioral effects of ganstigmine (CHF2819), a novel acetylcholinesterase inhibitor, in rat prefrontal cortex: an in vivo study.
    Trabace L; Cassano T; Colaianna M; Castrignanò S; Giustino A; Amoroso S; Steardo L; Cuomo V
    Pharmacol Res; 2007 Oct; 56(4):288-94. PubMed ID: 17822918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus.
    Trabace L; Coluccia A; Gaetani S; Tattoli M; Cagiano R; Pietra C; Kendrick KM; Cuomo V
    Brain Res; 2000 May; 865(2):268-71. PubMed ID: 10821930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.
    Smith CP; Bores GM; Petko W; Li M; Selk DE; Rush DK; Camacho F; Winslow JT; Fishkin R; Cunningham DM; Brooks KM; Roehr J; Hartman HB; Davis L; Vargas HM
    J Pharmacol Exp Ther; 1997 Feb; 280(2):710-20. PubMed ID: 9023283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease.
    Abe Y; Aoyagi A; Hara T; Abe K; Yamazaki R; Kumagae Y; Naruto S; Koyama K; Marumoto S; Tago K; Toda N; Takami K; Yamada N; Ori M; Kogen H; Kaneko T
    J Pharmacol Sci; 2003 Sep; 93(1):95-105. PubMed ID: 14501158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
    Bores GM; Huger FP; Petko W; Mutlib AE; Camacho F; Rush DK; Selk DE; Wolf V; Kosley RW; Davis L; Vargas HM
    J Pharmacol Exp Ther; 1996 May; 277(2):728-38. PubMed ID: 8627552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of MF-268, a new cholinesterase inhibitor, on acetylcholine and biogenic amines in rat cortex.
    Zhu XD; Cuadra G; Brufani M; Maggi T; Pagella PG; Williams E; Giacobini E
    J Neurosci Res; 1996 Jan; 43(1):120-6. PubMed ID: 8838583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats.
    Ohara T; Tanaka K; Fukaya H; Demura N; Iimura A; Seno N
    Behav Brain Res; 1997 Feb; 83(1-2):229-33. PubMed ID: 9062691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.
    Liang YQ; Tang XC
    Neurosci Lett; 2004 May; 361(1-3):56-9. PubMed ID: 15135892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats.
    Liang YQ; Tang XC
    Acta Pharmacol Sin; 2006 Sep; 27(9):1127-36. PubMed ID: 16923332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntheses and anticholinesterase activity of tetrahydrobenzazepine carbamates.
    Chen YL; Liston D; Nielsen J; Chapin D; Dunaiskis A; Hedberg K; Ives J; Johnson J; Jones S
    J Med Chem; 1994 Jun; 37(13):1996-2000. PubMed ID: 8027982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the acetylcholinesterase inhibitor ENA-713 on ischemia-induced changes in acetylcholine and aromatic amine levels in the gerbil brain.
    Tanaka K; Ogawa N; Asanuma M; Hirata H; Kondo Y; Nakayama N; Mori A
    Arch Int Pharmacodyn Ther; 1993; 323():85-96. PubMed ID: 8250645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of MDL 73,745 on acetylcholine and biogenic amine levels in rat cortex.
    Zhu XD; Giacobini E; Hornsperger JM
    Eur J Pharmacol; 1995 Mar; 276(1-2):93-9. PubMed ID: 7781701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dual-acting AChE inhibitor and H3 receptor antagonist UW-MD-72 reverses amnesia induced by scopolamine or dizocilpine in passive avoidance paradigm in rats.
    Sadek B; Khan N; Darras FH; Pockes S; Decker M
    Physiol Behav; 2016 Oct; 165():383-91. PubMed ID: 27568232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleus basalis magnocellularis lesions: lack of biochemical and immunocytochemical recovery and effect of cholinesterase inhibitors on passive avoidance.
    Thal LJ; Dokla CP; Armstrong DM
    Behav Neurosci; 1988 Dec; 102(6):852-60. PubMed ID: 3214535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats--Is there a potential for Alzheimer's disease treatment?
    Misik J; Korabecny J; Nepovimova E; Kracmarova A; Kassa J
    Neurosci Lett; 2016 Jan; 612():261-268. PubMed ID: 26708634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel carbamate cholinesterase inhibitors that release biologically active amines following enzyme inhibition.
    Verheijen JC; Wiig KA; Du S; Connors SL; Martin AN; Ferreira JP; Slepnev VI; Kochendörfer U
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3243-6. PubMed ID: 19423342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions.
    de Lago E; Ortega-Gutiérrez S; Ramos JA; López Rodríguez ML; Fernández-Ruiz J
    Life Sci; 2007 Feb; 80(10):979-88. PubMed ID: 17173937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.